Back to results
US 12,509,702 B2Granted
Inducible modification of a cell genome
AssigneeAstraZeneca AB
InventorsMarcello Maresca, Mohammad Bohlooly-Yeganeh, Himjyot Jaiswal, Lorenz M. Mayr, Xiufeng Xu
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
Claims9
A method of modifying a cell genome, comprising:
- introducing into a cell a first engineered nucleic acid comprising
- (a) a promoter operably linked to a nucleic acid encoding a Cas9 nuclease that does not comprise a nuclear localization signal, wherein the nucleic acid encoding the nuclease is flanked by estrogen receptor (ERT2) sequences
- wherein the engineered nucleic acid comprises the sequence of SEQ ID NO:7;
- and
- (b) a deoxyribonucleic acid (DNA)-binding nuclease recognition sequence;
- introducing into the cell a second engineered nucleic acid comprising a promoter operably linked to a nucleic acid encoding a guide RNA (gRNA) that targets a genomic region of the cell;
- and
- incubating the cell in the presence of tamoxifen under conditions that result in modification of the cell genome.
5 more elements
A transgenic mouse comprising a genome comprising an engineered nucleic acid construct comprising the sequence of SEQ ID NO:
- 7.
A transgenic mouse comprising a genome comprising an engineered nucleic acid construct comprising the sequence of any one of SEQ ID NO:
- 8 or 12-20.
Dependencies are inferred from the claim text.